Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!

Szczegóły
Abstrakt

Tytuł:: Immunoglobulins in the treatment of COVID-19 infection: Proceed with caution!
Autorzy:: Nguyen AA; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America.
Habiballah SB; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America.
Platt CD; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America.
Geha RS; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America.
Chou JS; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America.
McDonald DR; Division of Immunology, Boston Children's Hospital, Boston, MA, United States of America. Electronic address: .
Źródło:: Clinical immunology (Orlando, Fla.) [Clin Immunol] 2020 Jul; Vol. 216, pp. 108459. Date of Electronic Publication: 2020 May 11.
Typ publikacji:: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
Język:: English
Imprint Name(s):: Original Publication: Orlando, FL : Academic Press, c1999-
MeSH Terms:: Pandemics*
Betacoronavirus/*drug effects
Coronavirus Infections/*drug therapy
Cytokine Release Syndrome/*pathology
Immunoglobulins, Intravenous/*administration & dosage
Immunologic Factors/*administration & dosage
Pneumonia, Viral/*drug therapy
Adaptive Immunity/drug effects ; Angiotensin-Converting Enzyme 2 ; Antibody-Dependent Enhancement/drug effects ; Betacoronavirus/immunology ; Betacoronavirus/pathogenicity ; COVID-19 ; Coronavirus Infections/epidemiology ; Coronavirus Infections/immunology ; Coronavirus Infections/therapy ; Coronavirus Infections/virology ; Cytokine Release Syndrome/etiology ; Cytokine Release Syndrome/immunology ; Cytokine Release Syndrome/prevention & control ; Gene Expression ; Humans ; Immunity, Innate/drug effects ; Immunization, Passive/adverse effects ; Immunization, Passive/methods ; Immunoglobulins, Intravenous/adverse effects ; Immunologic Factors/adverse effects ; Molecular Targeted Therapy ; Peptidyl-Dipeptidase A/genetics ; Peptidyl-Dipeptidase A/immunology ; Pneumonia, Viral/epidemiology ; Pneumonia, Viral/immunology ; Pneumonia, Viral/virology ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus/genetics ; Spike Glycoprotein, Coronavirus/immunology ; T-Lymphocytes/drug effects ; T-Lymphocytes/immunology ; T-Lymphocytes/virology ; COVID-19 Serotherapy
References:: Clin Infect Dis. 2011 Feb 15;52(4):447-56. (PMID: 21248066)
Eur J Clin Microbiol Infect Dis. 2005 Jan;24(1):44-6. (PMID: 15616839)
Biotechnol Adv. 2011 Mar-Apr;29(2):239-47. (PMID: 21146601)
Nat Rev Immunol. 2013 Mar;13(3):176-89. (PMID: 23411799)
Nat Med. 2020 Jun;26(6):845-848. (PMID: 32350462)
Open Forum Infect Dis. 2020 Mar 21;7(3):ofaa102. (PMID: 32258207)
PLoS Med. 2006 Jul;3(7):e237. (PMID: 16796401)
Vaccine. 2019 Sep 3;37(37):5535-5543. (PMID: 31160101)
J Virol. 2020 Feb 14;94(5):. (PMID: 31826992)
PLoS Med. 2006 Sep;3(9):e343. (PMID: 16968120)
Vaccine. 2017 Jul 13;35(32):3922-3929. (PMID: 28633892)
Cell. 2020 Apr 16;181(2):281-292.e6. (PMID: 32155444)
JCI Insight. 2019 Feb 21;4(4):. (PMID: 30830861)
Chest. 2013 Aug;144(2):464-473. (PMID: 23450336)
Emerg Infect Dis. 2004 May;10(5):818-24. (PMID: 15200814)
Emerg Infect Dis. 2016 Sep;22(9):1554-61. (PMID: 27532807)
J Hepatol. 2020 Aug;73(2):409-422. (PMID: 32333923)
JAMA. 2003 Jul 16;290(3):374-80. (PMID: 12865379)
Emerg Infect Dis. 2017 Jul;23(7):1079-1084. (PMID: 28585916)
Lancet Infect Dis. 2020 May;20(5):565-574. (PMID: 32213337)
Asian Pac J Allergy Immunol. 2020 Mar;38(1):1-9. (PMID: 32105090)
Pediatr Allergy Immunol. 2016 Feb;27(1):22-7. (PMID: 26480951)
Grant Information:: K08 AI076625 United States AI NIAID NIH HHS; K08 AI116979 United States AI NIAID NIH HHS; R01 AI139633 United States AI NIAID NIH HHS
Contributed Indexing:: Keywords: COVID-19; Coronavirus; Hyperimmune globulin; Intravenous immunoglobulin; SARS-CoV-2
Substance Nomenclature:: 0 (Immunoglobulins, Intravenous)
0 (Immunologic Factors)
0 (Spike Glycoprotein, Coronavirus)
0 (spike protein, SARS-CoV-2)
EC 3.4.15.1 (Peptidyl-Dipeptidase A)
EC 3.4.17.23 (ACE2 protein, human)
EC 3.4.17.23 (Angiotensin-Converting Enzyme 2)
Entry Date(s):: Date Created: 20200519 Date Completed: 20200713 Latest Revision: 20240319
Update Code:: 20240319
PubMed Central ID:: PMC7211658
DOI:: 10.1016/j.clim.2020.108459
PMID:: 32418917
: Czasopismo naukowe

Full Text Finder

The COVID-19 pandemic is one of the greatest infectious challenges in recent history. Presently, few treatment options exist and the availability of effective vaccines is at least one year away. There is an urgent need to find currently available, effective therapies in the treatment of patients with COVID-19 infection. In this review, we compare and contrast the use of intravenous immunoglobulin and hyperimmune globulin in the treatment of COVID-19 infection.
Competing Interests: Declaration of Competing Interest The authors declare no conflicts of interest.
(Published by Elsevier Inc.)

Informacja